Abstract:Objective: To analyze the differentially expressed proteins in the dorsal raphe nucleus of rats treated with olanzapine and explore the possible mechanism of metabolic disorders in the early stage of olanzapine treatment. Methods: Twenty male and 20 female SD rats were both randomized equally into olanzapine group and control group for daily treatment with olanzapine and saline for 4 weeks, respectively. One hour after the last treatment, the dorsal raphe nucleus of the rats was dissected for proteomic analysis using iTRAQ combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS). GO, KEGG pathway, COG, pathways and protein interaction network analyses of the differentially expressed proteins were performed. Several target genes were selected from the proteomic list, and their expression levels in the dorsal raphe nucleus of another 24 mice with identical grouping and treatment using real time real-time quantitative PCR and Western blotting. Results: A total of 214 differentially expressed proteins were identified in the dorsal raphe nucleus of olanzapine-treated mice, including 72 unregulated and 142 downregulated proteins. GO analyses showed that the differentially expressed proteins were enriched in cellular process, biological regulation, metabolic process, response to stimulus, multicellular organismal process, bindings, catalytic activity, molecular function regulator and transcription regulator activity. KEGG analysis suggested that these proteins were enriched in fluid shear stress and atherosclerosis, serotonergic synapse, butanoate metabolism, thyroid hormone synthesis and IL-17 signaling pathway. The differentially expressed proteins Cav1, Hsp90b1, Canx, Gnai1, MAPK9, and LOC685513 were located at the nodes of the protein-protein interaction network in close relation with metabolic disorders. In olanzapine-treated mice, the expression of Hmgcs2, a negative regulator of apoptosis, was significantly down-regulated in the dorsal raphe nucleus, where the expressions of Pla2g4e, Slc6a4 and Gnai1 involved in serotonergic synapse were significantly upregulated. Conclusion: In the early stage of treatment, olanzapine may contribute to the occurrence of metabolic disorders in rats by regulating the expressions of Cav1, Hsp90b1, Canx, Gnai1, MAPK9, LOC685513 (Gng14) and 5-HTR2 synapse-related proteins in the dorsal raphe nucleus.

Similar Effects of Clozapine and Olanzapine on Ethanol-Induced Ascorbic Acid Release in the Prefrontal Cortex of Freely Moving Mice

Effects of olanzapine on the hypoglutamatergic schizophrenia model in mice

Olanzapine causes a leptin-dependent increase in acetylcholine release in mouse prefrontal cortex

Olanzapine Ameliorates Neuropathological Changes and Increases IGF-1 Expression in Frontal Cortex of C57BL/6 Mice Exposed to Cuprizone.

Effects of clozapine on the hypoglutamatergic schizophrenia model in mice

A Comparative Proteomics Analysis of Rat Mitochondria from the Cerebral Cortex and Hippocampus in Response to Antipsychotic Medications

Effect of Clozapine and Olanzapine on the Expression of Selected Genes and Epigenetic Regulators of Insulin Resistance Pathway in Human Preadipocytes – a Preliminary Study

The effect of ethyl alcohol on the function of spatial memory in rats

Bromocriptine and clozapine regulate dopamine 2 receptor gene expression in the mouse striatum

Time-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in rats

Distinct neural mechanisms underlying acute and repeated administration of antipsychotic drugs in rat avoidance conditioning

[Bioinformatic analysis of differentially expressed proteins in the dorsal raphe nucleus of rats after continuous treatment with olanzapine]

Olanzapine alleviates oxidative stress in the liver of socially isolated rats

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism

Glutamate Receptor 1 Phosphorylation at Serine 845 Contributes to the Therapeutic Effect of Olanzapine on Schizophrenia-Like Cognitive Impairments.

Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice

Up-regulation of hepatic fatty acid transporters and inhibition/down-regulation of hepatic OCTN2 contribute to olanzapine-induced liver steatosis

Olanzapine and Risperidone Disrupt Conditioned Avoidance Responding by Selectively Weakening Motivational Salience of Conditioned Stimulus: Further Evidence

Effect of olanzapine on glucose metabolism and its mechanism

Olanzapine's effects on hypothalamic transcriptomics and kinase activity

Olanzapine, but not haloperidol, exerts pronounced acute metabolic effects in the methylazoxymethanol rat model